Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

被引：0
|
作者：
Leif Bjermer
Job F. M. van Boven
Madlaina Costa-Scharplatz
Dorothy L. Keininger
Florian S. Gutzwiller
Karin Lisspers
Ronan Mahon
Petter Olsson
Nicolas Roche
机构：
[1] Skane University Hospital,Department of Respiratory medicine & Allergology
[2] Lund University,Department of General Practice
[3] Groningen Research Institute for Asthma and COPD (GRIAC),Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy
[4] University Medical Center Groningen,Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine
[5] University of Groningen,Respiratory and Intensive Care Medicine
[6] University of Groningen,undefined
[7] Novartis Sverige AB,undefined
[8] Novartis Pharma AG,undefined
[9] Uppsala University,undefined
[10] Novartis Ireland Limited,undefined
[11] Cochin Hospital (AP-HP) and University Paris Descartes,undefined
来源：
Respiratory Research | / 18卷
关键词：
Chronic obstructive pulmonary disease; Indacaterol/glycopyrronium; Cost-effective; Exacerbation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 42 条
  • [1] Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
    Bjermer, Leif
    van Boven, Job F. M.
    Costa-Scharplatz, Madlaina
    Keininger, Dorothy L.
    Gutzwiller, Florian S.
    Lisspers, Karin
    Mahon, Ronan
    Olsson, Petter
    Roche, Nicolas
    RESPIRATORY RESEARCH, 2017, 18
  • [2] Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients
    Bjermer, Leif
    van Boven, Job F. M.
    Costa-Scharplatz, Madlaina
    Gutzwiller, Florian S.
    Lisspers, Karin
    Mahon, Ronan
    van der Molen, Thys
    Olsson, Petter
    Roche, Nicolas
    Burke, Colin
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [3] Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
    Anzueto, Antonio R.
    Kostikas, Konstantinos
    Mezzi, Karen
    Shen, Steven
    Larbig, Michael
    Patalano, Francesco
    Fogel, Robert
    Banerji, Donald
    Wedzicha, Jadwiga A.
    RESPIRATORY RESEARCH, 2018, 19
  • [4] Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
    Antonio R. Anzueto
    Konstantinos Kostikas
    Karen Mezzi
    Steven Shen
    Michael Larbig
    Francesco Patalano
    Robert Fogel
    Donald Banerji
    Jadwiga A. Wedzicha
    Respiratory Research, 19
  • [5] DELAYED TIME TO FIRST AND SUBSEQUENT EXACERBATIONS INDEPENDENT OF SEASON WITH INDACATEROL/GLYCOPYRRONIUM COMPARED WITH SALMETEROL/FLUTICASONE: THE FLAME STUDY
    Banerji, D.
    Chapman, K.
    Kostikas, K.
    Olsson, P.
    Thach, C.
    Patalano, F.
    Fogel, R.
    RESPIROLOGY, 2018, 23 : 157 - 157
  • [6] Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
    Wedzicha, Jadwiga A.
    Zhong, Nanshan
    Ichinose, Masakazu
    Humphries, Michael
    Fogel, Robert
    Thach, Chau
    Patalano, Francesco
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 339 - 349
  • [7] AN ECONOMIC EVALUATION OF INDACATEROL/GLYCOPYRRONIUM COMPARED WITH TIOTROPIUM AND SALMETEROL/FLUTICASONE FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THAILAND
    Boonsawat, W.
    Geater, S. L.
    Burke, C.
    Numuang, K.
    RESPIROLOGY, 2016, 21 : 180 - 180
  • [8] Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach
    Lakhotia, Bhavesh
    Mahon, Ronan
    Gutzwiller, Florian S.
    Danyliv, Andriy
    Nikolaev, Ivan
    Thokala, Praveen
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 787 - 797
  • [9] COST-EFFECTIVENESS ANALYSIS OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) VS SALMETEROL/FLUTICASONE (SFC) AS MAINTENANCE TREATMENT FOR COPD PATIENTS IN TAIWAN: UPDATED BASED ON THE RESULTS OF THE FLAME STUDY
    Tan, E. C. H.
    Yang, M. C.
    VALUE IN HEALTH, 2019, 22 : S352 - S352
  • [10] COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINATION INDACATEROL/GLYCOPYRRONIUM VS. TIOTROPIUM AND SALMETEROL/FLUTICASONE IN THE MANAGEMENT OF COPD IN GREECE
    Geitona, M.
    Kousoulakou, H.
    Kalogeropoulou, M.
    Mitsiki, E.
    Panitti, E.
    Steiropoulos, P.
    VALUE IN HEALTH, 2015, 18 (07) : A500 - A500
12345